Global Journal of Medical Research, F: Diseases, Volume 22 Issue 4

tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ. 1994; 308: 1323-1328. 7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352(9131): 837-53. 8. Tapp RJ, Zimmet PZ, Harper CA, de Courten MP, McCarty DJ, Balkau B et al. Diagnostic thresholds for diabetes: the association of retinopathy and albuminuria with glycaemia. Diabetes Res ClinPract. 2006; 73: 315-321. 9. American Diabetic Association. Standards of medical care in diabetes- 2007 [Position Statement]. Diabetes Care. 2007; 30(1): 4-41. 10. Ito C, Maeda R, Ishida S, Sasaki H and Harada H. Correlation among fasting plasma glucose, two- hour plasma glucose levels in OGTT and HbA1c. Diabetes Res ClinPract. 2000; 50: 225-230. 11. Sabanayagam C, Liew G, Tai ES, Shankar A, Lim SC, Subramaniam T and Wong TY. Relationship between glycated hemoglobin and microvascular complications: Is there a natural cut-off point for the diagnosis of diabetes? Diabetologia. 2009; 52: 1279- 1289. 12. Hernandez D, Espejo-Gil A, Bernal-Lopez MR, Mancera-Romero J, Baca-Osorio AJ, Tinahones FJ et al. Association of HbA1c and cardiovascular and renal disease in an adult Mediterranean population. BMC Nephrology. 2013; 14: 151. 13. Patel A, MacMaho S, Chalmers J, Neal B, Billot L, Woodward M et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-2572. 14. Kumar HKVS, Kota SK, Basile A and Modi KD. Profile of microvascular disease in type 2 diabetes in a tertiary health care hospital in India. Ann Med Health Sci Res. 2012; 2(2): 103-108. 15. Agrawal RP, Ranka M, Beniwal R, Sharma S, Purohit VP, Kochar DK and Kothari RP. Prevalence of micro and macro vascular complications in type 2 diabetes and their risk factors. Int. J. Diab. Dev. Countries. 2004; 24: 11-16. 16. Giorgino F, Laviola L, Perin PC, Solnica B, Fuller JandChaturvedi N. Factors associated with progression to microalbuminuria in micro- albuminuric Type 1 diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia. 2004; 47: 1020-1028. 17. Fava S, Azzopardi J, Hattersley AT and Watkins PJ. Increased prevalence of proteinuria in diabetic sibs of proteinuric type 2 diabetic subjects. Am J Kidney Dis. 2000; 35(4): 708- 712. 18. Nelson RG, Knowler WC, Pettitt DJ, Saad MF and Bennett PH. Diabetic kidney disease in Pima Indians. Diabetes Care. 1993; 16(1): 335-341. 19. Adler AI, Steven RJ, Manley SE, Bilous RW, Cull CA and Rury R. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney International. 2003.63. p. 225-232. 20. American Diabetes Association. Diabetic Nephropathy. Diabetes Care 2003; 26(S1): S94– 8. 21. ADA: Self monitoring of blood glucose (Consensus statement). Diabetes Care 1987; 10(1): 95–99. 22. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brwn DM, Goetz FC. Structural– functional relationships in diabetic nephropathy. J Clin Invest 1984; 74: 1143–55. 23. Sabanayagam C, Liew G, Tai ES, Shankar A, Lim SC, Subramaniam T and Wong TY. Relationship between glycated hemoglobin and microvascular complications: Is there a natural cut-off point for the diagnosis of diabetes? Diabetologia. 2009; 52: 1279-1289. 24. Hernandez D, Espejo-Gil A, Bernal-Lopez MR, Mancera-Romero J, Baca-Osorio AJ, Tinahones FJ et al. Association of HbA1c and cardiovascular and renal disease in an adult Mediterranean population. BMC Nephrology. 2013; 14: 151. 25. Zoungas S, Chalmers J, Ninomiya T, Li Q, Cooper ME, Colagiuri S et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia. 2012; 55: 636-643. 26. Drummond KN, Kramer MS, Suissa S, Levy- Marshal C, Dell’ Aniello S, Sinaiko Alan, et al. Effects of duration and age at onset of type 1 diabetes on preclinical manifestations of nephropathy. Diabetes 2003; 52(7): 1818–24. 27. Donaghue KC, Fairchild JM, Craig ME, Chan AK, Fracnzo SH, Cutler LR, et al. Do all prepubertal years of diabetes duration contribute equally to diabetes complications? Diabetes Care 2003; 26: 1224–9. 28. Holl RW, Grabert M, Thon A, Heinze E. Urinary excretion of albumin in adolescents with type 1 diabetes. Diabetes Care 1999; 22(9): 1555–60. 29. Zhang L, Krzentowski G, Albert A, Lefebvre PJ. Risk of developing retinopathy in Diabetes Control and complications trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 2001; 24(7): 1275–9. 30. The DCCT. Research group: the effect of intensive treatment of diabetes on the development and progression of long term complications in insulin- dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86. 31. D’Antonio JA, Ellis D, Doft BH, Becker DJ, Drash AL, Kuller LH, et al. Diabetes complications and 7 Year 2022 Global Journal of Medical Research Volume XXII Issue IV Version I ( D ) F © 2022 Global Journals To Evaluate the Role of HbA1C as a Predictor for the Development of Diabetic Nephropathy in Type 1 Diabetic Patients